Yuxin Chen , Zecheng Yu , Huazhong Ying , Fangwei Dai , Wei Han
{"title":"新城疫病毒在临床神经肿瘤疾病中的应用前景","authors":"Yuxin Chen , Zecheng Yu , Huazhong Ying , Fangwei Dai , Wei Han","doi":"10.1016/j.bbadis.2025.168025","DOIUrl":null,"url":null,"abstract":"<div><div>Newcastle disease virus (NDV) can activate an anti-tumour immune response, and the virus has tumour-lysing properties and can induce apoptosis in tumour cells. NDV is used as a vector in oncolytic virus therapy, which has the unique advantage of tumour-specific inflammation activation, and drug resistance avoidance, resulting in the killing of tumour cells and induction of systemic anti-tumour immunity. NDV uses cancer signalling pathways to transform the immune-desert and microenvironment and immune-rejecting tumours into immunoinflammatory tumours, activating innate and adaptive anti-tumour immune responses to kill tumour cells, and its clinical application is one of the emerging cancer therapies focused on by researchers with good prospects for translational applications. The article reviews the mechanisms of NDV infection and oncolysis, and the clinical applications and safety of tumour oncolysis in nervous system tumours. This may contribute to enhancing further intervention and treatment of neurological tumours with NDV and lay the foundation for the widespread clinical use of NDV as a neoadjuvant therapeutic treatment.</div></div>","PeriodicalId":8821,"journal":{"name":"Biochimica et biophysica acta. Molecular basis of disease","volume":"1871 8","pages":"Article 168025"},"PeriodicalIF":4.2000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prospect of Newcastle disease virus in clinical neurological tumour diseases\",\"authors\":\"Yuxin Chen , Zecheng Yu , Huazhong Ying , Fangwei Dai , Wei Han\",\"doi\":\"10.1016/j.bbadis.2025.168025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Newcastle disease virus (NDV) can activate an anti-tumour immune response, and the virus has tumour-lysing properties and can induce apoptosis in tumour cells. NDV is used as a vector in oncolytic virus therapy, which has the unique advantage of tumour-specific inflammation activation, and drug resistance avoidance, resulting in the killing of tumour cells and induction of systemic anti-tumour immunity. NDV uses cancer signalling pathways to transform the immune-desert and microenvironment and immune-rejecting tumours into immunoinflammatory tumours, activating innate and adaptive anti-tumour immune responses to kill tumour cells, and its clinical application is one of the emerging cancer therapies focused on by researchers with good prospects for translational applications. The article reviews the mechanisms of NDV infection and oncolysis, and the clinical applications and safety of tumour oncolysis in nervous system tumours. This may contribute to enhancing further intervention and treatment of neurological tumours with NDV and lay the foundation for the widespread clinical use of NDV as a neoadjuvant therapeutic treatment.</div></div>\",\"PeriodicalId\":8821,\"journal\":{\"name\":\"Biochimica et biophysica acta. Molecular basis of disease\",\"volume\":\"1871 8\",\"pages\":\"Article 168025\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biochimica et biophysica acta. Molecular basis of disease\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0925443925003734\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochimica et biophysica acta. Molecular basis of disease","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0925443925003734","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Prospect of Newcastle disease virus in clinical neurological tumour diseases
Newcastle disease virus (NDV) can activate an anti-tumour immune response, and the virus has tumour-lysing properties and can induce apoptosis in tumour cells. NDV is used as a vector in oncolytic virus therapy, which has the unique advantage of tumour-specific inflammation activation, and drug resistance avoidance, resulting in the killing of tumour cells and induction of systemic anti-tumour immunity. NDV uses cancer signalling pathways to transform the immune-desert and microenvironment and immune-rejecting tumours into immunoinflammatory tumours, activating innate and adaptive anti-tumour immune responses to kill tumour cells, and its clinical application is one of the emerging cancer therapies focused on by researchers with good prospects for translational applications. The article reviews the mechanisms of NDV infection and oncolysis, and the clinical applications and safety of tumour oncolysis in nervous system tumours. This may contribute to enhancing further intervention and treatment of neurological tumours with NDV and lay the foundation for the widespread clinical use of NDV as a neoadjuvant therapeutic treatment.
期刊介绍:
BBA Molecular Basis of Disease addresses the biochemistry and molecular genetics of disease processes and models of human disease. This journal covers aspects of aging, cancer, metabolic-, neurological-, and immunological-based disease. Manuscripts focused on using animal models to elucidate biochemical and mechanistic insight in each of these conditions, are particularly encouraged. Manuscripts should emphasize the underlying mechanisms of disease pathways and provide novel contributions to the understanding and/or treatment of these disorders. Highly descriptive and method development submissions may be declined without full review. The submission of uninvited reviews to BBA - Molecular Basis of Disease is strongly discouraged, and any such uninvited review should be accompanied by a coverletter outlining the compelling reasons why the review should be considered.